findmyKOL
Clinical trialNCT00067626CompletedPhase 2Interventional

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

SponsorGriffin HospitalEnrollment60Impaired Fasting GlucoseImpaired Glucose ToleranceInsulin ResistanceObesityPre-diabetes
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David L Katz, MD, MPH

    Yale University/Yale-Griffin Prevention Research Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Yale-Griffin Prevention Research Center

    Derby, Connecticut, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2005
Primary completion
31 Mar 2009
Completion
31 Mar 2009
Last update posted
15 Oct 2010
Registered enrollment
60
Registry id
NCT00067626

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.